Analyst firms · Citigroup · PRME
Citigroup PRME price target and rating history
Prime Medicine Inc. (PRME) · Health Care
Citigroup rates Prime Medicine Inc. (PRME) Neutral with a $1.50 price target, as of its latest action on May 27, 2025. It has published 3 rating actions on PRME since December 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50.
- Current rating
- Neutral
- Price target
- $1.50
- Median target, all firms
- $8.50
- Actions on PRME
- 3
Citigroup price target on PRME
Every Citigroup rating on PRME
- May 27, 2025
- May 16, 2024
- Dec 8, 2023
How other firms rate PRME
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $7 | Aug 25, 2026 |
| BMO Capital Markets | Outperform | $9 | Aug 19, 2026 |
| H.C. Wainwright | Buy | $8 | Jun 29, 2026 |
| Oppenheimer | Outperform | $11 | Mar 12, 2026 |
Questions about Citigroup and PRME
- What is Citigroup's price target for PRME?
- Citigroup's latest stated price target for Prime Medicine Inc. (PRME) is $1.50, from its action on May 27, 2025.
- What is Citigroup's rating on PRME?
- Citigroup rates PRME Neutral, a neutral rating, as of May 27, 2025.
- When did Citigroup last change its view on PRME?
- On May 27, 2025, Citigroup downgrades to Neutral from Buy, price target $1.50.
- How does Citigroup's PRME target compare with other analysts?
- Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50.
More PRME rating histories
All Citigroup ratingsPRME news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.